Business Context and Reporting Period
This Form 8-K, dated November 6, 2020, reports the completion of a business combination between Rexahn Pharmaceuticals, Inc. (the "Company") and Ocuphire Pharma, Inc. (the "Ocuphire"). The transaction was structured as a reverse acquisition, with Ocuphire treated as the accounting acquirer. Following the merger, the Company changed its name to Ocuphire Pharma, Inc. and began trading on the Nasdaq Capital Market under the ticker symbol "OCUP" on November 6, 2020. The Company is a clinical-stage ophthalmic biopharmaceutical company focused on developing therapies for eye disorders.
Key Financial Metrics and Capital Structure
The filing details the post-merger capital structure and financing activities but does not provide specific revenue, profit, or cash flow figures for the combined entity in this report, as historical financial statements for Ocuphire are incorporated by reference from a separate Proxy Statement.
- Pre-Merger Financing: The Company completed a private placement raising approximately $21,150,000 from accredited investors immediately prior to the merger closing.
- Shares Outstanding: Immediately following the merger, there were approximately 7,091,878 shares of Common Stock outstanding. This excludes 3,749,992 "Converted Additional Shares" held in escrow for investors.
- Ownership Structure: Former Ocuphire stockholders and optionholders own approximately 86.6% of the fully-diluted Common Stock. Pre-merger Rexahn stockholders own approximately 13.4%.
- Exchange Ratio: The merger consideration was calculated using an exchange ratio of approximately 1.0565 shares of Common Stock for each share of Ocuphire common stock.
- Dilutive Securities: Post-merger, there are options to purchase 1,242,373 shares and warrants to purchase 231,433 shares outstanding.
- Reverse Stock Split: A 1-for-4 reverse stock split was effected on November 5, 2020, prior to the merger completion.
Material Changes Versus Prior Period
The filing represents a fundamental transformation of the registrant rather than a standard period-over-period financial comparison.
- Corporate Identity: The legal entity formerly known as Rexahn Pharmaceuticals, Inc. has been renamed Ocuphire Pharma, Inc.
- Business Focus: The Company's business has shifted from its prior operations to the clinical-stage ophthalmic biopharmaceutical business of Ocuphire.
- Accounting Treatment: For accounting purposes, the transaction is a reverse acquisition. Consequently, the historical financial statements of Ocuphire (audited by Ernst & Young, LLP) will serve as the historical financial statements of the Company, replacing those of Rexahn (audited by Baker Tilly US, LLP).
- Board and Management: The Board of Directors was reconstituted. Six directors from the pre-merger Rexahn board resigned, and six designees selected by Ocuphire were appointed. Mina Sooch was appointed President and CEO, replacing Douglas Swirsky.
Guidance, Outlook, Risks, and Unusual Items
The filing does not contain specific financial guidance or forward-looking revenue projections. However, it outlines several material agreements and contingencies:
- Contingent Value Rights (CVR): A CVR Agreement was entered into, providing rights to pre-merger stockholders based on future milestones or conditions detailed in the Proxy Statement.
- Investor Warrants and Escrow: Investors in the Pre-Merger Financing received Series A and Series B warrants. Additionally, 3,749,992 shares are held in escrow and may be released to investors if the trading price of the Common Stock falls below a specific threshold during the first ten trading days post-merger.
- Lock-Up Agreements: Financing Lock-Up Agreements and Leak-Out Agreements were executed with officers, directors, and investors to restrict share sales for a specified period.
- Executive Compensation: The former CEO, Douglas Swirsky, received a lump sum cash payment of $1,180,398 upon termination of employment. New employment agreements were executed for Mina Sooch (CEO) and Bernhard Hoffmann (VP of Corporate Development and Finance).
- Future Filings: Unaudited interim financial statements and pro forma financial information are scheduled to be filed by amendment within 71 calendar days of this report.
Important Facts for Investor Verification
- Verify the terms of the Contingent Value Rights (CVR) Agreement and the specific milestones required for payout.
- Confirm the release conditions for the 3,749,992 shares held in escrow and the impact of the "leak-out" provisions on near-term liquidity.
- Review the unaudited pro forma financial information (to be filed within 71 days) to understand the combined entity's cash position and burn rate.
- Monitor the trading volume and price of the Common Stock during the first ten trading days post-merger to determine if escrow shares will be released.
- Examine the Ocuphire 2020 Equity Incentive Plan to assess future dilution potential from the 1,000,000 new shares reserved plus up to 1,063,246 additional shares.